早期乳腺癌区域淋巴结放疗:16项试验14 324例女性个体患者数据Meta分析
该个体患者数据Meta分析纳入16项随机试验共14 324例早期乳腺癌女性,比较区域淋巴结放疗与不放疗。1989-2008年启动的8项较新试验(12 167例)中,区域淋巴结放疗显著降低复发(RR 0.88,95%CI 0.81-0.95;p=0.0008)、乳腺癌死亡率(RR 0.87,95%CI 0.80-0.94;p=0.0010)和全因死亡率(RR 0.90,95%CI 0.84-0.96;p=0.0022),对非乳腺癌死亡率无显著影响。1961-78年启动的8项较老试验(2157例)中,区域淋巴结放疗对乳腺癌死亡率几乎无影响(RR 1.04,95%CI 0.91-1.20;p=0.55),但显著增加非乳腺癌死亡率(RR 1.42,95%CI 1.18-1.71;p=0.00023)和全因死亡率(RR 1.17,95%CI 1.04-1.31;p=0.0067)。
要点
- 较新试验中区域淋巴结放疗显著降低复发、乳腺癌死亡和全因死亡。
- 较老试验中区域淋巴结放疗增加非乳腺癌死亡和全因死亡。
- 较新试验中非乳腺癌死亡率无显著影响(RR 0.97,95%CI 0.84-1.11;p=0.63)。
核心结论
- 1980年代后开展的试验中,区域淋巴结放疗显著降低乳腺癌死亡率和全因死亡率,而较老试验中未见此效果。
- 这些对比性发现可能反映1980年代以来放疗技术的改进。
研究设计与样本
- 个体患者数据Meta分析,检索MEDLINE、Embase、Cochrane Library及会议摘要等数据库,纳入2009年1月1日前启动的随机试验。
- 共找到17项合格试验,其中16项有可用数据(14 324例参与者),1项数据不可用(165例参与者)被排除。
- 治疗组间唯一系统性差异为区域淋巴结放疗(内乳链、锁骨上窝或腋窝,或任意组合)。
- 主要结局为任何部位复发、乳腺癌死亡率、非乳腺癌死亡率和全因死亡率。
- 采用对数秩分析得出首次事件率比(RR)和置信区间。
主要发现
- 8项较新试验(12 167例,1989-2008年启动)中,区域淋巴结放疗显著降低复发(RR 0.88,95%CI 0.81-0.95;p=0.0008),主要效应为远处复发。
- 较新试验中,区域淋巴结放疗显著降低乳腺癌死亡率(RR 0.87,95%CI 0.80-0.94;p=0.0010),非乳腺癌死亡率无显著影响(RR 0.97,95%CI 0.84-1.11;p=0.63),全因死亡率显著降低(RR 0.90,95%CI 0.84-0.96;p=0.0022)。
- 示例性计算中,15年乳腺癌死亡率估计绝对降幅:无阳性腋窝淋巴结女性为1.6%,1-3枚阳性腋窝淋巴结者为2.7%,4枚及以上阳性腋窝淋巴结者为4.5%。
- 8项较老试验(2157例,1961-78年启动)中,区域淋巴结放疗对乳腺癌死亡率几乎无影响(RR 1.04,95%CI 0.91-1.20;p=0.55),但显著增加非乳腺癌死亡率(RR 1.42,95%CI 1.18-1.71;p=0.00023),风险主要在20年后,并显著增加全因死亡率(RR 1.17,95%CI 1.04-1.31;p=0.0067)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Radiotherapy has become much better targeted since the 1980s, improving both safety and efficacy. In breast cancer, radiotherapy to regional lymph nodes aims to reduce risks of recurrence and death. Its effects have been studied in randomised trials, some before the 1980s and some after. We aimed to assess the effects of regional node radiotherapy in these two eras. METHODS: In this meta-analysis of individual patient data, we sought data from all randomised trials of regional lymph node radiotherapy versus no regional lymph node radiotherapy in women with early breast cancer (including one study that irradiated lymph nodes only if the cancer was right-sided). Trials were identified through the EBCTCG's regular systematic searches of databases including MEDLINE, Embase, the Cochrane Library, and meeting abstracts. Trials were eligible if they began before Jan 1, 2009. The only systematic difference between treatment groups was in regional node radiotherapy (to the internal mammary chain, supraclavicular fossa, or axilla, or any combinations of these). Primary outcomes were recurrence at any site, breast cancer mortality, non-breast-cancer mortality, and all-cause mortality. Data were supplied by trialists and standardised into a format suitable for analysis. A summary of the formatted data was returned to trialists for verification. Log-rank analyses yielded first-event rate ratios (RRs) and confidence intervals. FINDINGS: We found 17 eligible trials, 16 of which had available data (for 14 324 participants), and one of which (henceforth excluded), had unavailable data (for 165 participants). In the eight newer trials (12 167 patients), which started during 1989-2008, regional node radiotherapy significantly reduced recurrence (rate ratio 0·88, 95% CI 0·81-0·95; p=0·0008). The main effect was on distant recurrence as few regional node recurrences were reported. Radiotherapy significantly reduced breast cancer mortality (RR 0·87, 95% CI 0·80-0·94; p=0·0010), with no significant effect on non-breast-cancer mortality (0·97, 0·84-1·11; p=0·63), leading to significantly reduced all-cause mortality (0·90, 0·84-0·96; p=0·0022). In an illustrative calculation, estimated absolute reductions in 15-year breast cancer mortality were 1·6% for women with no positive axillary nodes, 2·7% for those with one to three positive axillary nodes, and 4·5% for those with four or more positive axillary nodes. In the eight older trials (2157 patients), which started during 1961-78, regional node radiotherapy had little effect on breast cancer mortality (RR 1·04, 95% CI 0·91-1·20; p=0·55), but significantly increased non-breast-cancer mortality (1·42, 1·18-1·71; p=0·00023), with risk mainly after year 20, and all-cause mortality (1·17, 1·04-1·31; p=0·0067). INTERPRETATION: Regional node radiotherapy significantly reduced breast cancer mortality and all-cause mortality in trials done after the 1980s, but not in older trials. These contrasting findings could reflect radiotherapy improvements since the 1980s. FUNDING: Cancer Research UK, Medical Research Council.
引用
- Radiotherapy to regional nodes in early breast cancer: an individual patient data meta-analysis of 14 324 women in 16 trials. Lancet. 2023. PMID: 37931633. doi:10.1016/S0140-6736(23)01082-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。